samedan logo
 
 
spacer
home > epc > autumn 2006 > herbal medicinal products: the need for regulation
PUBLICATIONS
European Pharmaceutical Contractor

Herbal Medicinal Products: The Need for Regulation

Dr Jung Wing Wan of Pharmalink Consulting Ltd ponders the quality, safety and efficacy considerations of herbal products, and examines the development of regulations inside and outside Europe

Herbal medicines have been used extensively to treat a broad range of medical conditions. Recent years have witnessed an increase in their use, but questions remain concerning their quality, safety and efficacy (QSE). From a quality point of view, there must be an assurance that the herbal product is what it claims to be. It may be more difficult to characterise a herbal product – usually a variable and complex mixture of chemical components – than a conventional pharmaceutical drug. With respect to safety, the potential side effects, as well as any possible interactions with other drugs, must be fully understood. Finally, it is important to establish the efficacy of the herbal medicine when used to treat a given condition. Equipped with this knowledge, it becomes easier to identify how herbal medicines can be used with minimal adverse effects on the patient. Selected regulatory agencies in Europe and the US have already implemented measures to accommodate the requirements for establishing the QSE of herbal medicinal products, distinct from QSE requirements for conventional pharmaceutical drugs.

Herbal medicines have been developed and used by man for thousands of years (1). Plants have formed the basis of sophisticated traditional medicine systems, among which are Ayurvedic (2), Arabic (3) and Chinese (4). Many of the pharmaceuticals available to Western physicians today have a long history of use as herbal remedies, such as opium, aspirin, digitalis and quinine.

The use of herbs to treat disease is almost universal among nonindustrialised societies. In developing countries, as much as 80 per cent of the indigenous populations depend on medicinal plants and traditional systems of medicine as their primary source of healthcare. Within the European Community, herbal medicines account for an important share of the pharmaceutical market, with annual sales in the range of US$7 billion. In the US alone, the sale of herbal medicines exceeded $3.3 billion in 1997 (5). The accurate scientific assessment of herbal medicine is a prerequisite for global harmonisation of herbal health claims. In a recent World Health Organization (WHO) report (6), the following was highlighted:


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Jung Wing Wan is currently a Senior Regulatory Consultant for Pharmalink Consulting Ltd, having worked on a number of European regulatory projects with multinational pharmaceutical clients. Prior to joining Pharmalink Consulting Ltd in 2004, he worked for GlaxoSmithKline, managing international vaccine registrations. Jung completed his PhD in Chemistry at the University of Southampton in 1997. His first degree in Chemistry from the University of East Anglia included a year as an exchange student at the INSA de Rouen University in France. With a keen interest in languages, he is also fluent in Chinese, French and Spanish.
spacer
Dr Jung Wing Wan
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

ELNs & Advanced Laboratory Solutions

27-29 September 2010, Marriott Hotel, Amsterdam, The Netherlands

Increase your research efficiency, accelerate workflow and enhance geo-separate collaboration by establishing a clear e-laboratory environment in your company. Building on the resounding success of last year’s event, Europe’s leading forum for data management and ELNs professionals will provide you with a key platform to discuss and find out how others are tackling the main challenges faced in the data management space, as well as the opportunity to network with your peers and forge new contacts in this area.
More info >>

 
News and Press Releases

Almac launch Biomarkers for biopharma

Almac today announced the launch of Biomarkers for biopharma; a range of solutions specifically designed to meet the needs of the biopharma industry. Almac’s solutions are to support biopharma companies in adopting biomarker strategies to enable them to better understand their drug, improve their drug’s success rate, improve the drug’s value and ultimately maximise their drug’s potential.
More info >>

 

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement